BOEHRINGER INGELHEIM and ViraTherapeutics announced a long-term collaboration to develop a next-generation oncolytic virus therapy platform and to investigate the ViraTherapeutics lead candidate VSV-GP (Vesicular Stomatitis Virus glycoprotein) alone and in combination with other therapies. ViraTherapeutics has developed its technology with joint support from its lead investors EMBL Ventures and Boehringer Ingelheim Venture Fund and...
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
